TÝOTROPÝUM KULLANAN KOAH’LILARIN KOMORBÝDÝTELERÝ

Amaç: KOAH multisistemik bir hastalýktýr ve komorbid hastalýklarýn varlýðý KOAH morbiditesini etkilemektedir. Bu çalýþmada amacýmýz tiotropium kullanan KOAH hastalarýnda komorbidite sýklýðýný belirlemektir. Materyal ve Metod: 2013 yýlýnda Türkiye’de Reçete Bilgi Sistemi’nden alýnan verileri kullanýlarak ICD-10 taný kodlama sistemine göre reçetede bulunan tanýlar kaydedildi. Bulgular: Tiotropium reçetelenmiþ 877.040 reçetede toplam 1.957.223 taný olduðu saptandý. Baþlýca komorbiditeler %24,2 oraný ile kardiyovasküler hastalýklar, %16,9 ile gastrointestinal sistem hastalýklarý, %12,7 ile kas-iskelet sistem hastalýklarý, %9,4 ile endokrinolojik hastalýklar ve %6,4 diðer semptomlar olarak belirlendi.KOAH ile birlikte ilaç reçetelenen hastalarýn %16,2’sýnda hipertansiyon, % 8,9’unda Gastroözofajial reflü hastalýðý (GERH), %5,4’ünde miyalji, %4,6’sýnda diyabet, % 4’ünde aterosklerotik kardiyovasküler hastalýk, %3,6’sýnda peptik ülser, öne çýkan tanýlar olarak dikkati çekmektedir. Sonuç: KOAH ülkemizde komorbiditeleri yoluyla direkt ve dolaylý olarak ekonomik maliyeti giderek artan bir saðlýk sorunudur. Sorunlarýn çözülebilmesi için ulusal týbbi kayýt sistemleri kullanýlarak yapýlan epidemiyolojik çalýþmalara ihtiyaç vardýr.

CO-MORBIDITIES OF PATIENTS WITH COPD USING TIOTROPIUM

Aim: COPD is a multisystemic disease and the morbidity from COPD may be affected by other comorbid chronic conditions. The aim of our study was to assess the frequency of comorbidities in COPD patients taking tiotropium. Material and methods: According to the 2013 Turkey Recipe Information System’s data, prescriptions included Tiotropium were selected and identified recorded other diagnoses together with COPD focusing on ICD-10-codes. Results: A number of total prescription was 877.040 and a number of total diagnosis was 1.957.223. Main comorbidities were determined as cardiovascular disease with 24,2%, gastrointestinal system disorder with 16,9%, musculoskeletal impairments with 12,7%, endocrinological diseases with 9,4%, other symptoms with 6,4%. As prominent diagnoses of patients prescribed medication with COPD, were hypertension in 16,2% gastroesophageal reflux disease (GERD) in 8,9%, myalgia in 5,4%, diabetes in 4,6%, atherosclerotic cardiovascular disease in 4%, and peptic ulcer in 3,6%. Conclusion: COPD is speculated as a health burden having both direct and indirect costs via comorbidities in our country. The economic impact of COPD is only going to worsen. It is necessary to conduct epidemiologic studies performed using national medical record data to improve overall outcomes.